ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly oncology — U.S. revenue ($M) ($M)
Form 10-Q / 10-K Note 2 Disaggregated Revenue
Latest, FY2025
5,352
Period ended Dec 31, 2025
Change on a year earlier
+6.3%
5,036 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Oncology — U.S. revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5,352 | +6.3% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 5,036 | +32.6% | Form 10-K (filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 3,797 | +18.0% | Form 10-K (filed 2026-02-12) ↗ |
| FY2022 | Dec 31, 2022 | 3,218 | +6.3% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 3,029 | +8.5% | Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 2,792 | +7.0% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 2,609 | +8.5% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 2,403 | +17.2% | Form 10-K (filed 2021-02-17) ↗ |
| FY2017 | Dec 31, 2017 | 2,050 | +3.8% | Form 10-K (filed 2020-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 1,975 | – | Form 10-K (filed 2019-02-19) ↗ |
Breakdown
What makes up oncology — u.s. revenue ($m)
Cite this data
StockData. (2026). Eli Lilly Oncology — U.S. revenue ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ta_oncology_us
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.